SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

Monash University

Status and phase: Completed; Phase 3

Conditions: Heart Failure

Treatments: Drug: Placebo; Drug: Spironolactone

Study type: Interventional

Funder types: Other

Identifiers

NCT00604006

CP-02/07

Details and patient eligibility

About

Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.

Enrollment: 20 patients

Sex: All

Ages: 60+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Was recruited to SCREEN-HF
2. Has provided informed consent

Exclusion criteria

1. Uncorrected hyperkalaemia
2. eGFR < 30 ml/min

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

20 participants in 2 patient groups, including a placebo group

Group A

Experimental group

Treatment:

Drug: Spironolactone

Group B

Placebo Comparator group

Treatment:

Drug: Placebo